Grown Rogue International (GRUSF) Income from Non-Controlling Interests (2019 - 2026)
Grown Rogue International (GRUSF) recorded quarterly Income from Non-Controlling Interests of -$488826.0 in Q1 2026, up 100.0% quarter-over-quarter from -$321.7 billion in Q4 2025, and down 239.26% on a YoY basis from $351029.0 in Q1 2025.
Grown Rogue International (GRUSF) Income from Non-Controlling Interests (2019 - 2026) Analysis & Trends
Grown Rogue International's Income from Non-Controlling Interests history runs 8 years deep, the most recent figure standing at -$488826.0 for Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests fell 239.26% year-over-year to -$488826.0; the TTM figure through Mar 2026 stood at -$182.1 billion (down 29.91% YoY), while the FY2025 annual figure was -$1.5 million, down 5450.36% from the prior year.
- Income from Non-Controlling Interests was -$488826.0 for Q1 2026 at Grown Rogue International, up from -$321.7 billion in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $139.6 billion in Q3 2025 to a low of -$321.7 billion in Q4 2025.
- Historically, Income from Non-Controlling Interests has averaged -$21.5 billion across 5 years, with a median of $30728.0 in 2024.
- The sharpest annual moves came in 2022 and 2024: Income from Non-Controlling Interests soared 11432.01% in 2022, then sank 915246585.72% in 2024.
- A 5-year view of Income from Non-Controlling Interests shows it stood at $564607.0 in 2022, then sank by 94.76% to $29607.0 in 2023, then tumbled by 915246585.72% to -$271.0 billion in 2024, then fell by 18.72% to -$321.7 billion in 2025, then jumped by 100.0% to -$488826.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$488826.0 (Q1 2026), -$321.7 billion (Q4 2025), and $139.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | - |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 22.56 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | - |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | - |
| 10 | Grown Rogue International | - | - | 3.96 Mn | -488,826.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -488,826.00 |
| Dec 31, 2025 | -321.70 Bn |
| Sep 30, 2025 | 139.57 Bn |
| Jun 30, 2025 | 99,131.00 |
| Mar 31, 2025 | -144,088.00 |
| Dec 31, 2024 | -270.98 Bn |
| Sep 30, 2024 | 130.78 Bn |
| Jun 30, 2024 | 80,039.42 |
| Mar 31, 2024 | 30,728.00 |
| Dec 31, 2023 | 29,607.00 |
| Oct 31, 2023 | 210,129.00 |
| Jul 31, 2023 | 119,093.00 |
| Apr 30, 2023 | -867.00 |
| Jan 31, 2023 | -339,408.00 |
| Jan 31, 2022 | 564,607.00 |
| Oct 31, 2021 | 1.12 Mn |
| Jul 31, 2021 | 283,126.00 |
| Apr 30, 2021 | -15,306.00 |
| Jan 31, 2021 | 4,896.00 |
| Oct 31, 2020 | -38,608.00 |